In a retrospective meta-analysis, we merged clinical (Figure 2A) and survival (Figures 2B,C) data from 10 independent experiments in which 93 mice received (i) donor BM cells + Tconvs (GVHD control group) or (ii) donor BM cells + Tconvs + Tregs (treatment 1) or (iii) donor BM cells + Tconvs + Tregs + anti-TNFR2 (treatment 2), an additional treatment that inhibited Treg effect, as previously reported (19). Here, TNFRSF1B is linked to graft versus host disease.